Rank: Advanced Member Groups: Member
Joined: 11/8/2009
Posts: 32
Location: Spain
|
Well, I have been able to contact biomaxx on WF10 and I copy the email they sent to me. I believe is quite interesting and as you can see some questions araise... but it´s late in Spain and I´ve to get up soon tomorrow, so I leave the plain email without any comment. It´ll be very appreciated any comment on the information they provide.
Good night.
___________________
First of all please forgive me my poor English but I do my best to make it understandable.
Yes we use Immunokine (WF10) more than 10 years and we have very good experience with this preparation by different types of cancer, by chronic inflammations and also by chronic infections but only by round about 40 ALS-patients within the last 3 years. That’s not a lot of patients but we can say in general Immunokine is very helpful and can reduce or eliminate the symptoms. That means one of the most important results is a better life quality and in conclusion our data show that under the conditions used it may inhibit the expected effects.
I am sorry, it nearly impossible to explain by an email letter why it works and how it works. Anyway, we are happy to have a weapon against ALS, not an end solution. See some more information on the end of this email.
How to use:
I give you a brief impression about Immunokine treatment in principle:
A complete "course" needs 3 x 5 weeks; the complete course has 3 equal parts
Part I
1. INFUSION WEEK
5 days (day by day) Immunokine infusion with some other components (High-Doses-Vitamin C, B-complex, Glutathione etc.)
1 week rest
2. INFUSION WEEK
3 days infusion (day by day)
1 week rest
3. INFUSION WEEK
3 days infusion (day by day)
2 weeks rest
Part II (3 infusion weeks)
…the same like Part I
2 weeks rest
Part III (3 infusion weeks)
the same like Part I
Total course within 14 weeks needs 33 treatments (infusions). Yes, it’s a long treatment term but even successful.
The Immunokine dose is depending of the body weight but we use a bit more (20%) than the "normal" doses by cancer or as you can find in the general protocols: 0.75ml per kg body weiht. For example: 50kg x 0.75ml = round about 40ml; 2 vials.
Infusion time: minimum 3 hours.
We suggest to all of our patients to realize parallel an Oxygen-Multistep-Therapy, very simple but very helpful as well; that treatment support the Immunokine extremely.
The patient can do everything in home situation, just an educated nurse should setup the infusion; intravenously but absolute harmless.
Expensive:
Our (internal) purchase price by our supplier is THB 6,500,- ˜ 168,- € for 1 vial. Including an small profit we give our out patients a price of 180,- €.
We recommend our patients to order as well the other components in Thailand because it's much cheaper than everywhere else.
Calculation for 1 complete infusion:
- Approximate by 50kg body weight: 2 vials Immunokine solution: 2 x 180,- € = 360,- €
- 1 Vitamin-C solution (high dose; 25g): 25,- €
- Vitamin-B-1, 6, 12 solution (normal dose of B1, B6, B12): 15,- €
- Glutathione (10ml Solution): 10,- €
Total per infusion: 410,- €
Total complete course, 33 infusions: 33 x 410,- € = 13,530 €.
Minimum order by this low price is a complete course (33 treatments) Shipping EMS Thailand to Europe: 250,- €
Payment: 100% in advance
(By the way: It sounds expensive but Immunokine isn’t really expensive in comparison to other ALS preparation without benefit.)
Following some scientific basic information:
Introduction
Immunokine i.v. belong to the class of translational therapeutics T. he active principle is the inorganic ion Chlorite (CLO2-) which via the PI3K-NADPH-MPO pathway modulates inappropriate immunologic activation by driving inflammatory cell apoptosis and enhancing the resolution of inflammation.
Resolution of inflammation requires the effective down regulation of key inflammatory cells such as neutrophils and eosinophils which normally undergo programmed cell death (apoptosis)to enable their detection and removal by phagocytes such as macrophages (Rossi 2006). Removal of apoptotic cells by functional macrophages is a key mechanism for the successful solution of acute and chronic inflammation. Enhanced inflammatory cell apoptosis and enhanced phagocytosis of apoptotic cells (cells with phagocytic capacity are not only macrophages and dendritic cells but also hepatocytes, endothelial cells and epithelial cells) is therefore a promising therapeutic option.
Dysregulation of this “on” and “off” process leads to necrosis instead of apoptosis and thereby contributes to the pathogenesis and progression of chronic inflammatory diseases such as persistent allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatic disease or inflammatory bowel disease (Hallett 2008).
The chronic inflammatory process produces mediators, which do not stop but rather supports cancer growth, i.e. Phophoinositide-3-kinase (P I3K) is activated. Activated PI3K induces anti-apoptotic pathways associated with high risk for cancer development. All cancers are associated with high PI3K activation. It is noteworthy to remind that in the past it was thought that inflammation is needed to inhibit cancer growth.
Immunokine effectively down regulates inflammatory cells in humans already after one treatment cycle (5 consecutive infusions of 0.5 ml per kg BW). For example intracellular macrophage T NF-alpha expression is markedly elevated in patients with inflammatory neurodegenerative diseases like ALS or Dementia. Immunokine (WF10) treatment of blood from patients with dementia showed a marked down regulation of macrophage TNF-alpha expression suggesting the neutralization of this neurotoxin (Herndier et al. 2000). Hepatitis C infected Patients who had high gene expression of pro-inflammatory genes like IL-1f3, TNF-alpha, MlP-1alpha and beta etc all were uniform down regulated to normal values associated with resolution of inflammation (Isensee, Giese 2002).
In an animal model (collagen induced arthritis) Immunokine enhanced the clearance of accumulated granulocytes at the peak of inflammation, an effect associated with an increased number of apoptotic cells (Sack 2007). In patients with cervix or colon cancer who had radiotherapy induced chronic inflammation (post radiation syndrome like cystitis and proctitis) Immunokine effectively terminated the inflammation in the bladder and intestines as well as acute and chronic bleeding within 2 days (Vutisiri et all, 2004) Massive Oedema following radiation of Glioblastoma Stage IV and unresponsive to glucocorticoid treatment could be markedly reduced with Immunokine infusions within 2 days and clinically impressive terminated in 4 weeks (Eyb 2006).
Metabolism
Whereas Chlorite (CL02-) as the active principle of Immunokine reacts fast to Chloride (CL-) and Oxygen (O2) thereby inducing a longterm and significant Oxygen saturation in patients with progressed cancer disease (Dümke, Fleckenstein, Vaupel 1996) from 40 ppm to 80 ppm. Via the compound I (MPO-H202) complex it produces endogenously stable oxidants like Taurinchloramin (Giese 2005) and Monochloramin (Arnold 2006). Immunokine might also replace function of dysfunctional Myeloperoxidase (Arnhold 2007).
Taurin Chloramine (TN-CI) is one of the most abundant compounds generated by activated neutrophils and eosinophils. TN-CI is a most potent inducer of apoptosis in inflammatory and tumour cells (Shacter 2005).
Immunokine generated Taurinchloramine more then 100-fold in human cells (PBMC) (this levels were stable for 24 hours) and effectively inhibited Phophoinositide-3-kinase (PI3K gamma) and increased apoptosis (Arnhold 2006).
Phosphoinositide-3-kinase critically regulates the recruitment and survival of neutrophils and eosinophils in vivo. Eosinophils are effector cells that play an important role in the pathophysiology of allergic disease.
In allergic rhinitis or asthma, eosinophils are a crucial source of cytotoxic proteins, lipid mediators, oxygen metabolites, and cytokines like lL-4 and IL13, which contribute to the severity of the disease.
Meuer (2008) found marked inhibition of IL-4 and IL-13 (the latter are key cytokines involved in allergic inflammation) in 37 individuals treated with and without Immunokine.
Pinho et al. (2005) investigated the role of PI3K for the recruitment and survival of eosinophils into the pleural cavity of antigen-challenged and sensitized mice (PI3K gamma -/- male C57BU6 or BALB/c mice supplied by Taconic Farms, Inc. Germantown, N.Y. They also investigated the effect of PI3K inhibitors. Treatment with PI3K inhibitors (Wortmannin and LY294002) 24 hours after antigen challenge markedly cleared the accumulated eosinophils, an effect associated with inhibition of Akt phosphorylation and increased apoptosis. (See also Cortez-RetamozoV. et al. J. Clin. Invest. 6 Nov 2008) The phagocyte NADPH oxidase is a multicomponent enzyme complex mediating microbial killing. Phosphoinositides regulate several distinct steps in NADPH activation, such as phosphorylation of p47phox in human neutrophils and eosinophils (Perisic et al 2004).
Individuals with p4Tphox mutations were found to have high incidence of rheumatoid arthritis (Hallstrom 2006). Intracellular production of superoxide is reduced by PI3K inhibitors (Wortmannin and LY 294002).
Treatment of activated PBMC's with Immunokine demonstrated a dose dependent inhibition of superoxide. This was associated with markedly increased bacterizidie (Hänsch 2006). There are plentiful data demonstrating that Immunokine (WF10) is an anti-inflammatory drug (not anti-pro-inflammatory) exerting concurrent powerful innate immunity. This is a new mechanism of immune modulation with clinical benefit in chemotherapeutic cancer treatment associated with high risk for infection. In a clinical trial in 102 women with cervix cancer high significant less antibiotic or antiinfective comedication was needed (Vutisiri 2004).
MPO-Immunokine can replace function of Myeloperoxidase (MPO)
That’s all for the moment.
I wish all the best and warmest regards from Bangkok
|